Albany, NY -- (SBWIRE) -- 04/14/2020 -- Actinic Keratosis Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Actinic Keratosis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The United States had the highest Actinic Keratosis prevalence with 66,733,101 cases in 2017.
2. The male-to-female ratios of Actinic Keratosis patients differ among various countries, but a male excess is a consistent finding among all countries except Italy.
3. Among the EU5 countries, Germany had the highest Actinic Keratosis prevalent population with 8,294,972 cases followed by the United Kingdom with a prevalent population of 5,419,455 in 2017. On the other hand, Japan has the lowest prevalent population with 700,954 cases in 2017.

Key benefits of the report
1. Actinic Keratosis market report covers a descriptive overview and comprehensive insight of the Actinic Keratosis epidemiology and Actinic Keratosis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Actinic Keratosis market report provides insights on the current and emerging therapies.
3. Actinic Keratosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Actinic Keratosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Actinic Keratosis market.

Request for sample pages

"Actinic Keratosis prevalence is higher among men than women of the same age."

The Actinic Keratosis market is available with several treatment options. The prevalence of Actinic Keratosis is increasing widely. Factors leading to increased prevalence include cumulative ultraviolet radiation exposure, increasing age, and childhood sun exposure, male working more in outdoors and resident of the population in latitudes that is close to equators.

Actinic Keratosis treatment mainly includes the lesion-directed and the field-directed therapies, in which one is directed at individual lesions, and the other therapy is for a full area.

The Actinic Keratosis therapeutics market is segmented widely into three primary therapies that include the lesion-directed destructive therapies (cryosurgery, curettage, laser, dermabrasion, surgery), field- directed topical therapies (imiquimod, diclofenac sodium, ingenol mebutate, 5-fluorouracil), and Photodynamic therapies(Ameluz, Levulan Kerastick, Metvixia cream, Alacare).

Besides this, specific off- label drugs are also used sometimes that includes Colchicine and Tretinoin. Destructive therapy remains the standard of care for lesion- directed treatment. Laser therapy and cryopeeling hold almost similar market share, although less than cryotherapy and surgery. Dermabrasion holds the lowest market share. Owing to efficacy, tolerability, compliance, and affordability, destructive therapy covers the largest market share than other treatments available (topical and PDT).

The launch of the emerging therapies is expected to significantly impact Actinic Keratosis treatment scenario in the upcoming years:-
Drugs covered
1. KX01 Ointment
2. VDA-1102
3. SOR 007
And many others

The key players in Actinic Keratosis market are:
1. Athenex
2. Vidac Pharma
3. DFB Soria

And many others

Table of contents

1. Key Insights
2. Executive Summary of Actinic Keratosis
3. Actinic Keratosis Market Overview at a Glance
4. Actinic Keratosis Disease Background and Overview
5. Actinic Keratosis Epidemiology and Patient Population
6. Country Wise-Epidemiology of Actinic Keratosis Disease
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. United Kingdom
6.8. Japan
7. Actinic Keratosis Treatment Practices
8. Current Unmet Needs
9. Actinic Keratosis Marketed Drugs
9.1. Aldara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)
9.2. Zyclara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)
9.3. Solaraze: Sandoz Pharmaceuticals
9.4. Efudex: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)
9.5. Carac: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)
9.6. Picato: LEO Pharma
9.7. Actikerell: Almirall S.A.
9.8. Fluoroplex: Aqua Pharmaceuticals
9.9. Ameluz: Biofrontera
9.10.Metvixia: Galderma
9.11.Levulan Kerastick: DUSA Pharmaceuticals
9.12.Alacare: Photonamic GmbH & Co. KG
9.13.Eryfotona AK-NMSC SPF 100+ Fluid: ISDIN Corp
10. Key Cross Competition
11. Actinic Keratosis Emerging Drugs
11.1.KX01 Ointment: Athenex
11.2.VDA-1102: Vidac Pharma
11.3.SOR 007: DFB Soria
12. Actinic Keratosis 7 Major Market Analysis
13. The United States Market Outlook of Actinic Keratosis
14. EU-5 Countries: Market Outlook
15. Germany Market outlook of Actinic Keratosis
16. France Market outlook of Actinic Keratosis
17. Italy Market outlook of Actinic Keratosis
18. Spain Market outlook of Actinic Keratosis
19. United Kingdom Market outlook of Actinic Keratosis
20. Japan Market outlook of Actinic Keratosis
21. Market Drivers
22. Market Barriers
23. SWOT Analysis
24. Reimbursement
25. KOL Views
26. Appendix
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight